Vnitr Lek 2024, 70(7):457-461 | DOI: 10.36290/vnl.2024.089

Current treatment options for ventricular arrhythmias in heart failure

Renáta Aiglová
Centrum pro diagnostiku a léčbu srdečního selhání
I. interní klinika - kardiologická FN a LF UP Olomouc

Despite advances in care, heart failure is still associated with a poor prognosis. Arrhythmic complications also contribute to the poor prognosis of patients with heart failure. Ventricular arrhythmias occur very frequently in patients with heart failure. They can be the result of structural myocardial damage, but less often they can also cause de novo heart failure or worsen pre-existing heart failure. Treatment of ventricular arrhythmias in heart failure requires a comprehensive approach. The basis is the optimized therapy of heart failure. Non-pharmacological treatment is also an integral part - ICD implantation, catheter ablation. Catheter ablation reduces the incidence of recurrences of ventricular arrhythmias and is a life-saving procedure in the event of an electrical storm.

Keywords: catheter ablation, pharmacotherapy, premature ventricular complexes, ventricular tachycardia, heart failure.

Accepted: October 24, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Aiglová R. Current treatment options for ventricular arrhythmias in heart failure. Vnitr Lek. 2024;70(7):457-461. doi: 10.36290/vnl.2024.089.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Málek F, Veselý J, Pudil R, et al. Souhrn Doporučených postupů Evropské kardiologické společnosti pro diagnostiku a léčbu srdečního selhání z roku 2021. Cor et Vasa. 2022;64:121-162. Go to original source...
    2. Melenovský V, Kautzner J, et al. Srdeční selhání pro klinickou praxi. Grada Publishing, a.s. 2023:246-260. ISBN 978-80-271-3732-9.
    3. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol. 1984;53:902. Go to original source... Go to PubMed...
    4. Cantillon DJ. Evaluation and management of premature ventricular complexes. Cleve Clin J Med. 2013;80:377-387. Go to original source... Go to PubMed...
    5. Desjardins B, et al. Infarct architecture and characteristics on delayed enhanced magnetic resonance imaging and electroanatomic mapping in patients with postinfarction ventricular arrhythmia. Heart Rhythm. 2009;6:644-651. Go to original source... Go to PubMed...
    6. Peichl P, et al. Management of ventricular arrhythmias in heart failure: Current perspectives. Heart Rhythm. 2021;2:796-809. Go to original source... Go to PubMed...
    7. Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997-4126. Go to original source... Go to PubMed...
    8. Wu S, et al. Catheter ablation of haemodynamically unstable or non-sustained ventricular tachycardia. Acta Cardiol. 2007;62:163-169. Go to original source... Go to PubMed...
    9. Scheen AJ. Dissecting the reduction in cardiovacular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death? Diabet Epidemiol Manag. 2022;100107. Go to original source...
    10. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993. Go to original source... Go to PubMed...
    11. Peichl P, et al. Complications of catheter ablation of ventricular tachycardia: a single-center experience. Circ Arrhythm Electrophysiol. 2014;7:684-690. Go to original source... Go to PubMed...
    12. Efremidis M, et al. Reversal of premature ventricular complex - induced cardiomyopathy following successful radiofrequency catheter ablation. Europace. 2008;10:769-770. Go to original source... Go to PubMed...
    13. Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552. Go to original source... Go to PubMed...
    14. Santangeli P, Rame JE, Birati EY, Marchlinski FE. Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. J Am Coll Cardiol 2017; 69:1842. Go to original source... Go to PubMed...
    15. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2. Go to original source... Go to PubMed...
    16. Jaïs P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012;125:2184. Go to original source... Go to PubMed...
    17. Romero J, Cerrud-Rodriguez RC, Di Biase L, et al. Combined Endocardial-Epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease: A Systematic Review and Meta-Analysis. JACC Clin Electrophysiol. 2019;5:13. Go to original source... Go to PubMed...
    18. Anderson RD, Ariyarathna N, Lee G, et al. Catheter ablation versus medical therapy for treatment of ventricular tachycardia associated with structural heart disease: Systematic review and meta-analysis of randomized controlled trials and comparison with observational studies. Heart Rhythm 2019;16:1484. Go to original source... Go to PubMed...
    19. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9. Go to original source...
    20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.